Innate Pharma Sa Financials
This page shows Innate Pharma Sa (IPHA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. All figures are derived from SEC filings (10-K and 10-Q reports).
The only clear operating signal is a modest reported revenue base, with FY2025 sales of $50.0M .
Against 93.7M shares outstanding,$50.0M of FY2025 revenue implies a small revenue-per-share base, so the missing profit and cash figures matter more than the top line for judging whether this scale is self-funding.
Because assets, liabilities, and cash flow are absent in the supplied annual row, this dataset cannot show whether FY2025 revenue converted into liquidity or reinvestment capacity; it only establishes activity level, not operating quality.
Some figures from recent filings were inconsistent and were omitted from this summary.
Key Financial Metrics
Earnings & Revenue
Innate Pharma Sa generated $50.0M in revenue in fiscal year 2025.
Cash & Balance Sheet
Innate Pharma Sa had 94M shares outstanding in fiscal year 2025.
Margins & Returns
Capital Allocation
IPHA Income Statement
Similar Companies
Frequently Asked Questions
What is Innate Pharma Sa's annual revenue?
Innate Pharma Sa (IPHA) reported $50.0M in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.